VEGFA and neoplasm: In melanoma cell models, BRAFV600 mutations can lead to decreased antitumor immunity through upregulation of immunosuppressive factors [e.g., IL-10, vascular endothelial growth factor (VEGF)] (58), elevation of PD-L1 expression levels (59), increased tumor infiltration of immunosuppressive cells (e.g., Treg) (60), and downregulation of melanoma MHC-1 expression (61).